Kabra Drugs informs about financial results

02 Feb 2019

In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Listing Regulations), Kabra Drugs has informed that the Unaudited Financial Results (Standalone) of the Company for the Quarter and Half-Year ended December 31, 2018 were approved by the Board of Directors of the Company at its meeting held.

The above information is a part of company’s filings submitted to BSE.

Related Kabra Drugs Ltd. Links:

Kabra Drugs Share Price

3.38 0.00 (0.00%) Nov 17, 18:55
1 Year Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 506.35
Dr. Reddys Lab 4806.45
Lupin 894.55
Piramal Enterprises 1388.85
Cadila Healthcare 421.20
View more..
Sensex vs Kabra Drugs
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback